A long-term goal of cancer diagnosis is to develop tumorimaging techniques that have sufficient specificity and sensitivity. To achieve this goal, minimizing the background signal originating from nontarget tissues is crucial. Here we achieve highly specific in vivo cancer visualization by using a newly designed targeted 'activatable' fluorescent imaging probe. This agent is activated after cellular internalization by sensing the pH change in the lysosome. Novel acidic pH-activatable probes based on the boron-dipyrromethene fluorophore were synthesized and then conjugated to a cancer-targeting monoclonal antibody. As proof of concept, ex vivo and in vivo imaging of human epidermal growth factor receptor type 2-positive lung cancer cells in mice was performed. The probe was highly specific for tumors with minimal background signal. Furthermore, because the acidic pH in lysosomes is maintained by the energy-consuming proton pump, only viable cancer cells were successfully visualized. The design concept can be widely adapted to cancer-specific, cell surface-targeting molecules that result in cellular internalization.
Genetic cell labeling techniques show the possibility of detecting or tracing a single cell in vivo [1] [2] [3] ; however, currently available injectable molecular imaging probes are limited in their ability to detect small volumes of viable cancer because of low target-to-background ratios. Generally, small molecular probes lack specificity and have low target accumulation; in contrast, larger molecules shows prolonged high retention and background 4 . However, such large-molecule complexes are cleared slowly, and thus a considerable amount of unbound probe remains. These pharmacokinetic characteristics result in high background signal (Fig. 1a) .
To overcome this problem, we developed an activatable fluorescence probe consisting of a cancer-targeting macromolecule and a smallmolecule fluorescent moiety activated only within cancer cells to minimize the background signal and maximize the tumor-to-normal tissue (T/N) ratio (Fig. 1b) .
We targeted the human epidermal growth factor receptor type 2 (HER2) with the monoclonal antibody trastuzumab, which, after binding to HER2, is internalized via the endosomal-lysosomal degradation pathway 5 .
The lysosome is distinct from other cellular organelles because of its low pH (pH 5.0-6.0) relative to the cytoplasm (pH B7.4). By designing a probe that becomes activated in an acidic environment, the agent yields a highly tumor-specific signal with greatly reduced background signal (Fig. 1c) .
RESULTS
Development of a tunable, pH-activatable fluorescent moiety To achieve signal activation within the acidic environment of the lysosome, we looked for small-molecule fluorescent molecules with the following characteristics: (i) they should be almost nonfluorescent in the extracellular environment, that is, at pH 7.4; (ii) they should become highly fluorescent under acidic conditions, that is, pH o 6; (iii) they need to be excited by long-wavelength light (Z500 nm) and emit a fluorescent signal that overcomes autofluorescence; (iv) they must covalently bind the targeting ligand or antibody; and (v) they must be tunable to different acid dissociation constant (pK a ) values for maximizing the T/N ratio. For developing probes, we employed the concept of photoinduced electron transfer (PeT). Briefly, if a chemical substrate reacts specifically with the target analyte and if its highest occupied molecular orbital or lowest unoccupied molecular orbital energy level changes markedly upon reaction, a fluorescence probe can be developed for the analyte by conjugating the substrate with an appropriate fluorophore [6] [7] [8] [9] .
To develop a series of acidic pH-sensitive fluorescence probes suitable to tag proteins, we selected anilines as the reactive moiety toward protons and a 2,6-dicarboxyethyl-1,3,5,7-tetramethyl boron-dipyrromethene (BODIPY) as a fluorophore 10 . BODIPYs are well known to show strong emission of wavelengths over 500 nm, and their fluorescence is unaffected by solvent polarity and pH. Furthermore, 2,6-dicarboxyethyl-1,3,5,7-tetramethyl-BODIPY has two carboxylic groups that can be used for coupling to proteins. N,Ndialkylated anilines have sufficiently high highest occupied molecular orbital energy levels to cause PeT toward the BODIPY fluorophore, and substitution of the N-alkyl group causes a pK a shift, so that it should be possible to develop a series of pK a -tunable compounds. On the basis of these strategies, we developed a series of unique, acidic pH-sensitive fluorescence probes bearing various anilines at the C8 position of the BODIPY fluorophore (Supplementary Methods online). These compounds were almost nonfluorescent (fluorescence quantum yield (F fl ) o 0.002) in the nonprotonated form, owing to PeT from the aniline moiety to the fluorophore, but became highly fluorescent (F fl ¼ 0.55-0.60) in the protonated form, showing a greater than 300-fold increase in emission (Fig. 2a and Supplementary Table 1 online) . Figure 2b shows the pH-dependent changes in emission intensity of acidic pH-sensitive probes, as well as the constant emission from pHindependent, 'always-on' BODIPY bearing benzene instead of aniline. The pK a values differed depending on the alkyl group on the nitrogen, ranging from 3.8 to 6.0 (Fig. 2c) .
Next, we conjugated these fluorescence probes to trastuzumab by using their mono-N-hydroxy-succinimidyl (NHS) ester derivatives to form an amide bond with lysine residues of the antibody. We selected conjugates with a degree of labeling (DOL) of 2.7-3.0 as optimal and evaluated their pH-dependent fluorescence emission intensity. The resulting probe-antibody conjugates produced acid-sensitive, reversible fluorescence ( 
conjugates labeled with unique fluorescence probes shown in Figure 2 with NIH3T3 HER2 + cells, a HER2 receptor-overexpressing cell line, and then obtained serial confocal microscopic images at selected time points. Fluorescence was confined to the plasma membrane on the image obtained immediately after addition of the always-on control probe (Fig. 3a) . After more than 2 h, small bright spots appeared inside the cells, probably corresponding to endosomal uptake of the probe (Fig. 3a) . These results indicate that the control probe shows strong fluorescence, regardless of its cellular location. In contrast, almost no fluorescence was observed immediately after the addition of the pH-activatable probes (Fig. 3a) . Because all probes were initially outside of the cells at neutral pH, the probe was still almost nonfluorescent. After 2 h, however, the probe conjugates were partially internalized by endocytosis, leading to the formation of endosomes. In the case of DiEtN-BDP-trastuzumab, some fluorescent spots were observed within the cells, but not on the plasma membrane, presumably reflecting the lowered pH inside the endosomes (Fig. 3a) . However, DiMeN-BDP-trastuzumab and EtMeN-BDP-trastuzumab produced few fluorescent spots inside the cells, 
suggesting that the environment of early endosomes is not sufficiently acidic to activate these compounds (Fig. 3a) . After 4 h, all activatable probes showed strongly fluorescent spots that co-localized with LysoTracker dyes within the cells (Fig. 3b) , and this activation lasted at least 1 d. These results show pH-dependent activation of the probe conjugates, and only the cells that internalized these probes became fluorescent, whereas the background fluorescence was minimal. Among a series of activatable probes, DiEtN-BDP-probe showed stronger signal than did DiMeN-BDP-and EtMeN-BDP-probes, and so we selected DiEtN-BDP-transtuzumab as a pH-activatable agent for further in vivo tumor imaging experiments.
In vivo imaging of HER2-positive lung metastases
To examine the potential of our approach for in vivo imaging, we performed in situ and ex vivo spectrally resolved fluorescence imaging of freshly resected lungs bearing metastatic genetically engineered NIH3T3 mouse fibroblast tumors overexpressing HER2 receptors with an always-on control probe and a pH-activatable probe. The control probe produced signals from non-tumor-bearing lung tissue and the heart, whereas the pH-activatable agent only produced signals from HER2-positive tumors, and the background fluorescence was suppressed (Fig. 4a) . As a result, the tumor-to-heart ratio of the pHactivatable probe (DiEtN-BDP-trastuzumab), which was calculated with 28 tumors of B1 mm in diameter (254 ± 5 pixels), was 22-fold higher than that of the control probe (193.0 versus 8.7 arbitrary units, Supplementary Table 2 online).
To confirm the specificity of this pH-activatable probe, we used a mixed metastatic lung tumor model of the HER2 + red fluorescent protein (RFP) -tumor cells and a HER2 -cell line with constitutively expressed RFP (RFP + HER2 -). The pH-activatable agent produced fluorescence only in HER2 + RFPtumors and not in RFP + HER2 -tumors (Fig. 4b) . In contrast, the control agent produced fluorescence not only in HER2 + RFP -tumors, but also in the surrounding tissues (Fig. 4b) . Additionally, the control agent produced yellow fluorescence in the control RFP + HER2 -tumors, owing to the mixing of red and green probes in the blood pool and interstitium.
Sensitivity and specificity determinations were made on the basis of evaluation of 22 mice with 940 tumors (468 and 472 with control and pH-activatable probes, respectively) with a size range between 0.5 mm and 2.0 mm. Comparison was made between the RFP + HER2 -cell line and the BODIPY-based probe (green) targeting the HER2 + RFP -cell line. On green or red fluorescence unmixed images, all 940 tumors were visible with the green, the red or both fluorescent signals (sensitivity 100% for both probes). Forty-eight of 468 tumors examined in mice with the control probe and three tumors of 472 tumors examined in mice with the pH-activatable probe showed both green and red florescence (the specificity was 84.8% and 99.1% for control and pH-activatable probes, respectively; see also Supplementary Table 3 online).
In addition, a control humanized antibody, pH-activatable daclizumab specific for the human interleukin-2 (IL-2) receptor a subunit 11 , which has 498% sequential homology to trastuzumab, did not show any fluorescence from the tumors (Fig. 4c) .
To show that pH-activatable probes produce fluorescence only from living cells, we loaded cells or tumors with either control or pHactivatable agent and then treated them with alcohol. Under fluorescence microscopy, the signal from pH-activatable probe-loaded cells disappeared immediately after addition of 30% ethanol, whereas the 
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NATURE MEDICINE VOLUME 15 [ NUMBER 1 [ JANUARY 2009 fluorescence signal from the control agent-loaded cells remained unchanged (Fig. 5a) . Moreover, the signal in tumors, visualized with the pH-activatable agent, significantly decreased 30 min after the tissues were dipped in ethanol (P o 0.001), whereas the signal in tumors visualized with the control agent showed minimal change (Fig. 5b,c) . The findings indicate that the signal from pH-activatable probes reflects cell viability.
To show the versatility of the method, we targeted mice reperesenting a peritoneal metastasis model of ovarian cancer with galactosamine-conjugated serum albumin (GSA) conjugated to the pH-activatable BODIPY. The in vitro and in vivo studies for detection and therapeutic monitoring of micrometastasis performed with the HER2-targeted probe in the lung metastasis model were repeated for the ovarian cancer model (Supplementary Figs. 1-4 online) . As we have shown in the HER2-overexpressing lung metastasis model, GSAbased target-specific pH-activatable probe against ovarian cancer achieved highly specific detection of peritoneal micrometastasis with minimal background fluorescence signal and successful real-time monitoring of anticancer therapeutic effects by decreasing fluorescence signal over time. Furthermore, in vivo fluorescence microendoscopic experiments in live mice bearing peritoneal ovarian cancer micrometastases were performed to show that the method is amenable to a laparoscopic approach (Supplementary Movies 2-4 online). Micrometastatic nodules invisible in regular white light endoscopic images were clearly detected with minimal background signal in fluorescence-guided endoscopic images enhanced with a GSA-based pH-activatable probe that facilitated the performance of endoscopic surgery and enabled validation of the resected tumors.
DISCUSSION
Fluorescence-based probes have the advantage that their signal is potentially switchable depending on local conditions and are now commonly used for visualizing cellular processes 12 . Nevertheless, few activatable fluorescence probes exist for in vivo imaging. Another group has developed activatable cyanine-based fluorescence probes based on cathepsin-mediated dequenching, resulting in a 12-fold increase in signal 13, 14 . Our approach differs in that a macromolecule is used to target the probe, and activation occurs after internalization in the low pH environment of the lysosome. The fluorescence yield is higher and the process is reversible.
A few pH-sensitive fluorescence probes are commercially available; however, most are poorly suited to in vivo imaging because they become activated with increasing pH 15 . Others become activated under acidic conditions, but their wavelengths are too short 16 , they are too hydrophobic and lack a tagging moiety for conjugation 17 or their background signal under neutral pH conditions is relatively high 18 . The probes described here are almost nonfluorescent at neutral pH and highly fluorescent at acidic pH. This high sensitivity, combined with high-specificity targeting, allows for the selective detection and monitoring of viable cancer cells in vivo.
Another advantage of our probe is that its activation is reversible, which enables the probe to produce signal only in viable cancer cells. Unlike previously reported irreversible activatable probes, our pHactivatable probes will lose signal upon leakage from the cell, as occurs with cell damage or death. Therefore, this method potentially permits real-time monitoring of therapy on living cancer cells 19 . In addition, this method could be useful to monitor the intracellular kinetics of receptor-ligand complexes.
Unlike other activatable probes 13, 20, 21 , DiEtN-BDP-trastuzumab consists of two independently functioning components: a targeted macromolecule (monoclonal antibody or GSA) and a pH-sensitive small-molecule fluorescence probe that is tunable and activatable. Therefore, this method could employ any antibody or cytokine that is internalized after receptor binding. In addition, not only can the pH threshold of the fluorescence be precisely tuned, but also the color (emission wavelength) can be changed by choosing different fluorophores, such as rhodamines 22 (Supplementary Movie 5 online).
Trastuzumab has a high binding affinity for the cell surface marker HER2/neu (erbB2 or p185) 23 and, therefore, could be potentially useful in HER2-expressing metastases 24, 25 . After forming homodimers, receptor-bound trastuzumab migrates to the lysosome as early as 45 min after binding 5 ; however, the internalization rate is B4% of bound antibody per hour 26 . Therefore, the use of more rapidly internalizing receptor-ligand systems, including the D-galactose receptor system 20, 27 ( Supplementary Figs. 1-4) , could yield more intense and earlier fluorescence signal. This agent could be adapted for clinical use with endoscopy or laparoscopy 28 and is potentially useful as an aid to surgery to improve the completeness of resection 29 .
In conclusion, we have developed small-molecule, pH-activatable fluorescence probes and have targeted them to viable cancer cells using macromolecule conjugates. These probe conjugates can potentially be used as in vitro tools for evaluating intracellular receptor kinetics, cell viability and real-time monitoring of cell death, although their main potential application will be as a clinical tool for cancer detection and real-time monitoring of therapy.
METHODS
Materials. General chemicals were of the best grade available, supplied by Aldrich Chemical, Tokyo Chemical Industries and Kokusan Chemical Works.
Antibodies. We purchased trastuzumab, a US Food and Drug Administrationapproved humanized monoclonal antibody to HER-2, which has a complimentarity-determination region against an epitope of HER-2 grafted onto a human IgG 1 framework, from Genentech (Herceptin). We purchased daclizumab, a US Food and Drug Administration-approved humanized monoclonal antibody to human CD25 (IL-2 receptor a subunit, IL-2Ra (Tac)), which has a complimentarity determination region against an epitope of CD25 grafted onto a human IgG 1 framework, from Hoffmann-La Roche (Zenapax).
Instruments. We recorded nuclear magnetic resonance (NMR) spectra on a JEOL JNM-LA300 instrument at 300 MHz for 1 H-NMR and 75 MHz for 13 C-NMR. We measured mass spectra with a JEOL JMS-T100LC AccuToF. We obtained ultraviolet-visible spectra on a JASCO V-550. We performed fluorescence spectroscopic studies on a JASCO FP-6500.
High-performance liquid chromatography. We performed preparative HPLC on a system composed of a pump (PU-2080, JASCO) and a detector (MD-2015, JASCO) with an Inertsil ODS-3 (10.0 mm Â 250 mm) column (GL Sciences).
Fluorometric analysis. The slit width was 3 nm for emission. The photomultiplier voltage was 300 V. We obtained the relative fluorescence quantum efficiency of BODIPY derivatives by comparing the area under the emission spectrum of the test sample excited at 490 nm with that of a solution of fluorescein in 0.1 N NaOH, which has a quantum efficiency of 0.850 according to the literature 30 .
Cell culture. We grew NIH3T3 HER2 + and Balb3T3 HER2 -RFP + cell lines 31 in RPMI 1640 (GIBCO) containing 10% FBS (GIBCO), 100 U ml -1 penicillin and 100 mg ml -1 streptomycin at 371 C in humidified air containing 5% CO 2 .
Labeling of trastuzumab with boron-dipyrromethene-mono-N-hydroxysuccinimidyl ester. We dissolved BODIPY-mono-NHS derivatives in DMSO to obtain 10 mM stock solutions. We incubated trastuzumab with BODIPYmono-NHS in 200 mM sodium phosphate buffer, pH 8.4, at 22 1C for 60 min in the dark. We separated the BODIPY-trastuzumab conjugate from free BODIPY by using a PD-10 column (GE Healthcare) and PBS pH 7.4 (GIBCO) as the eluent. Assuming that the protein was obtained without any loss at the separation step, we determined the DOL ratio (BODIPY [mol] / trastuzumab [mol]) by measuring the absorbance of the labeled trastuzumab at 520 nm.
Confocal imaging of internalization of the boron-dipyrromethene-labeled trastuzumab into NIH3T3 HER2 + cells. We incubated NIH3T3 HER2 + cells on poly-L-lysine-coated dishes in RPMI 1640 without phenol red. We added a solution of BODIPY-labeled trastuzumab in PBS pH 7.4 into the medium at a final concentration of 50 nM IgG. We obtained confocal images at selected times with a U-LH100HG confocal laser-scanning unit coupled to an IY81FVBF inverted microscope with a PlanApo Â60 objective lens (Olympus). The excitation wavelength was 488 nm and the emission was filtered with BA505IF filter.
Tumor model. All procedures were carried out in compliance with the US National Institutes of Health Guide for the Care and Use of Laboratory Animal Resources (1996) and the National Research Councils of the US and Japan and approved by the Animal Care and Use Committee of the National Institutes of Health or the University of Tokyo. We established the metastatic lung tumors by intravenous injection of 2 Â 10 6 tumor cells suspended in 200 ml of PBS in 8-week-old female nude mice (National Cancer Institute Animal Production Facility). We performed side-by-side comparative experiments with HER2 + lung metastatic tumor-bearing mice to directly compare always-on fluorophore-conjugated trastuzumab with pH-activatable fluorophore-conjugated trastuzumab for specificity and living cell monitoring at 19 d after injection of NIH3T3 HER2 + cells. We conducted two-color experiments with two injected cell lines of lung metastases in mice (RFP-transfected Balb3T3 HER2 -RFP + and 3T3 HER2 + ) to evaluate the specificity of HER2-expressing tumor detection at 12 d (Balb3T3 HER2 -RFP + ) and19 d (3T3 HER2 + ) after injection of cells 31 .
Fluorescence imaging in mice. We injected probes (50 nM) in 0.066 M PBS through the tail vein into tumor-harboring mice and left the mice alone for 1 d. Then we anesthetized and killed the mice and opened the thorax. We captured fluorescence images in the thorax with a Maestro In Vivo Imaging System (CRI). The excitation wavelength was 480-520 nm, and we obtained emission spectra from 500 nm to 800 nm. We created unmixed images with the use of authentic spectral patterns of BODIPY, RFP and the background 32 .
Note: Supplementary information is available on the Nature Medicine website.
